Biotech investing is an information war. The difference between a fund that returns 40% and one that loses money is often a single data point: a trial readout interpreted correctly, a regulatory signal caught early, a competitive pipeline shift identified before the market prices it in. The investors who win are the ones with the best information infrastructure.
Yet the tools landscape for biotech investing is fragmented and opaque. There is no single platform that does everything. Successful biotech investors assemble a stack of specialized tools — pipeline databases, clinical trial trackers, competitive intelligence platforms, regulatory monitors, and market analytics — that together create an information advantage.
This guide maps that stack. We profile 25 platforms that biotech investors, analysts, and BD professionals actually use to source deals, conduct due diligence, track pipelines, and make allocation decisions. Whether you are a healthcare-focused VC evaluating a Series B, a public biotech analyst building a DCF model, or a BD executive scouting licensing opportunities, these are the platforms that power your workflow.
This guide is updated quarterly. Platforms are evaluated on data quality, analytical depth, user adoption, and relevance to investment decision-making. Suggest a platform for review.
Why the Tools Stack Matters More Than Ever
Three dynamics are making biotech investment intelligence increasingly critical.
Capital is returning but selectivity is extreme. Biotech IPOs fell to their lowest level in over a decade in 2025 but are recovering in 2026. Investors are now most interested in companies with mature pipelines and positive clinical data. In this environment, the ability to quickly assess pipeline quality, clinical probability of success, and competitive positioning is the difference between deploying capital into winners and catching falling knives.
The patent cliff is creating a $200 billion reallocation. Over 200 major drugs face loss of exclusivity in the coming years. Big pharma companies hold nearly $1.4 trillion in cash and debt capacity for acquisitions. Every M&A target assessment, every licensing deal evaluation, and every pipeline gap analysis runs through the tools profiled below.
AI is generating more data than humans can process. With over 200 AI-designed drugs in clinical development, novel modalities proliferating, and clinical trial volumes at all-time highs, the sheer volume of relevant information has exceeded what any individual analyst can track manually. Tools that filter signal from noise are no longer nice-to-have — they are the cost of staying competitive.
Layer 1: Pipeline Databases & Drug Intelligence
These platforms provide the foundational data layer for biotech investing — comprehensive databases of drug pipelines, clinical development programs, and competitive landscapes that enable systematic analysis of therapeutic areas, companies, and individual assets.
1. Evaluate Pharma (Novaquest Capital)
Headquarters: London, UK
Evaluate Pharma is the industry standard for pharmaceutical revenue forecasting and pipeline valuation. Their consensus forecast models cover marketed drugs and pipeline candidates across the global pharmaceutical industry, enabling investors to model revenue trajectories, assess patent cliff exposure, and benchmark competitive positioning. Evaluate’s annual Pharma Preview report is one of the most widely cited forecasting documents in the industry. Their data underpins M&A target screening, licensing deal valuations, and portfolio construction decisions at virtually every major healthcare investment firm.
Best for: Revenue forecasting, pipeline valuation, patent cliff analysis, and M&A target screening.
2. Clarivate (Cortellis)
Headquarters: London, UK
Cortellis provides one of the most comprehensive drug pipeline databases in the world, covering hundreds of thousands of drug programs from discovery through commercialization. The platform integrates pipeline data with deal intelligence (licensing terms, partnership structures, acquisition prices), patent analytics, regulatory information, and competitive landscapes. BD and licensing teams at pharmaceutical companies use Cortellis as their primary tool for scouting acquisition targets and evaluating in-licensing opportunities. For investors, Cortellis provides the raw data needed to build competitive landscape maps and assess pipeline depth.
Best for: Pipeline intelligence, deal scouting, patent analytics, and competitive landscape mapping.
3. GlobalData
Headquarters: London, UK
GlobalData’s Pharma Intelligence platform combines drug pipeline tracking with analyst reports, epidemiology data, and market forecasts across all major therapeutic areas. Their coverage spans drugs, devices, and diagnostics, making it useful for investors evaluating companies that span multiple segments. GlobalData’s analyst team produces proprietary assessments of clinical probability of success and commercial potential that many buyside analysts use as inputs to their own models.
Best for: Broad pharmaceutical and medtech intelligence, epidemiology data, analyst-driven commercial assessments.
4. Citeline (Informa)
Headquarters: London, UK
Citeline encompasses several legacy intelligence brands — Pharmaprojects, Trialtrove, Sitetrove, and Biomedtracker — under one umbrella. Pharmaprojects provides drug pipeline data. Trialtrove tracks clinical trials. Biomedtracker is particularly valued by investors for its clinical event probability scores — quantitative assessments of the likelihood that a drug program will advance through each phase of development. These probability scores are widely used in biotech valuation models and probability-adjusted NPV calculations.
Best for: Clinical probability of success scoring, trial-level intelligence, and quantitative inputs for biotech valuation models.
5. BioCentury
Headquarters: Redwood City, CA
BioCentury occupies a unique position as both an intelligence platform and an editorial publication. Their BCIQ database provides pipeline tracking, deal data, and company profiles, while their editorial team produces the kind of deep analytical coverage that sophisticated investors use to understand strategic context. BioCentury’s conferences — particularly the annual Bernstein BioCentury Week — are among the most important gatherings for biotech investors and executives. For three decades, BioCentury has served biopharma executives, investors, and institutions with independent, deep-dive analysis.
Best for: Strategic analysis, deal context, executive-level intelligence, and investor-oriented editorial coverage.
6. Informa Pharma Intelligence (Datamonitor Healthcare)
Headquarters: London, UK
Datamonitor Healthcare (now part of Informa) provides epidemiology-based market forecasting that models the commercial opportunity for drug programs based on patient population dynamics, treatment rates, and market access assumptions. For investors building DCF models, Datamonitor’s patient-based forecasting provides a more granular foundation than top-down revenue estimates.
Best for: Patient-based commercial forecasting, epidemiology modeling, and market access analysis.
Layer 2: Clinical Trial Intelligence & Regulatory Tracking
These platforms track the clinical trials and regulatory decisions that drive biotech stock prices and deal activity. A single FDA decision or pivotal trial readout can move a company’s valuation by billions — making real-time access to this data essential.
7. ClinicalTrials.gov
Headquarters: Bethesda, MD (NIH/NLM) | Cost: Free
The U.S. National Library of Medicine’s ClinicalTrials.gov database is the single most important free resource for biotech investors. With over 500,000 registered clinical studies, it provides enrollment data, trial design details, primary and secondary endpoints, site locations, and status updates for virtually every interventional clinical trial worldwide. While the raw data requires interpretation, ClinicalTrials.gov is the foundation on which every other clinical trial intelligence platform builds.
Best for: Primary source clinical trial data, enrollment tracking, and protocol analysis.
8. Biomedtracker (Citeline)
Headquarters: London, UK
Biomedtracker deserves special mention beyond its parent Citeline because of its clinical event calendar and probability of success ratings. The platform tracks upcoming PDUFA dates, advisory committee meetings, clinical data presentations, and other catalysts that drive biotech stock movements. Their proprietary Likelihood of Approval (LOA) scores — quantitative estimates of the probability that a drug will progress from its current phase to FDA approval — are among the most widely used metrics in biotech investing. Many hedge funds and long-only healthcare funds use Biomedtracker as their primary catalyst tracking system.
Best for: Catalyst tracking, PDUFA date calendars, probability of approval scoring, and event-driven investment analysis.
9. TrialSight (Veeva)
Headquarters: Pleasanton, CA
Veeva’s TrialSight platform provides clinical trial analytics that help investors and sponsors understand competitive trial activity — which companies are running trials in specific indications, how enrollment compares across competing studies, and where site activity is concentrated. For investors, TrialSight’s competitive trial analysis reveals pipeline dynamics that are not visible from company press releases alone.
Best for: Competitive clinical trial analysis, enrollment benchmarking, and pipeline competitive intelligence.
10. FDA.gov (CDER, CBER, CDRH)
Headquarters: Silver Spring, MD | Cost: Free
The FDA’s own databases — including the CDER approval database, PDUFA date listings, Complete Response Letters, advisory committee calendars, and guidance documents — provide the primary source data for regulatory intelligence. Sophisticated investors monitor FDA databases directly rather than waiting for secondary coverage. The FDA’s Drug Approval Letters, Medical Reviews, and Summary Basis of Approval documents contain granular clinical and regulatory information that is invaluable for competitive analysis.
Best for: Primary source regulatory data, approval histories, advisory committee materials, and guidance tracking.
Layer 3: Market Data & Financial Analytics
These platforms provide the financial market data, valuation tools, and quantitative analytics that biotech investors use to size positions, build models, and execute trades.
11. Bloomberg Terminal
Headquarters: New York, NY
Bloomberg remains the dominant terminal for professional biotech investing. The BCLI (Bloomberg Intelligence Life Sciences) function provides dedicated healthcare analyst coverage, while the terminal’s drug pipeline data, clinical trial tracking, and M&A screeners are integrated directly into the financial workflow. Bloomberg’s PDUFA calendar, earnings estimates, and institutional ownership data make it the single-screen solution that many portfolio managers rely on.
Best for: Integrated financial and pipeline data, institutional ownership analysis, earnings models, and trade execution.
12. FactSet
Headquarters: Norwalk, CT
FactSet provides quantitative analytics, screening tools, and financial modeling capabilities that many healthcare analysts use alongside their pipeline intelligence platforms. Their integration with third-party pharmaceutical datasets allows analysts to combine financial data with clinical and pipeline information in customized workspaces. FactSet’s screening capabilities are particularly valued for identifying biotech companies that meet specific financial and pipeline criteria.
Best for: Quantitative screening, financial modeling, multi-source data integration, and portfolio analytics.
13. Sentieo / AlphaSense
Headquarters: New York, NY
AlphaSense (which acquired Sentieo) provides AI-powered search across financial documents — SEC filings, earnings transcripts, broker research, and expert interviews. For biotech investors, the ability to instantly search across thousands of earnings calls for mentions of specific drugs, indications, or competitive dynamics saves hundreds of hours of manual research. Their expert interview database (via Stream by AlphaSense) provides access to former industry executives and KOLs who can provide context that public data sources miss.
Best for: AI-powered document search, earnings call analysis, expert network access, and qualitative research.
14. Koyfin
Headquarters: New York, NY
Koyfin has emerged as a popular alternative to Bloomberg for biotech analysts who need financial data and charting without the six-figure terminal cost. Their platform provides stock screening, financial data, charting, and portfolio analytics with a clean interface that is particularly popular with emerging managers and individual biotech investors. While it lacks the pipeline-specific data of specialized platforms, Koyfin’s financial analytics capabilities complement them effectively.
Best for: Cost-effective financial data, screening, charting, and portfolio analytics for biotech-focused investors.
Layer 4: Deal Intelligence & M&A Tracking
These platforms track the licensing deals, partnerships, and acquisitions that reveal where pharmaceutical companies are deploying capital — often the best leading indicator of which therapeutic areas and modalities will drive returns.
15. DealForma
Headquarters: Needham, MA
DealForma provides the most granular biopharma deal database available, covering licensing agreements, co-development deals, asset acquisitions, and technology partnerships with detailed financial terms. For investors and BD professionals, understanding comparable deal structures — upfront payments, milestone schedules, royalty rates, and option terms — is essential for valuing pipeline assets and negotiating transactions. DealForma’s data is widely used in fairness opinions, board presentations, and investment committee memos.
Best for: Biopharma deal comp analysis, licensing term benchmarking, and transaction valuation.
16. PharmaDeals (Novaquest)
Headquarters: London, UK
PharmaDeals provides a comprehensive database of pharmaceutical business transactions alongside analytics that help users identify deal trends, compare transaction structures, and evaluate partnership terms. Their coverage spans licensing deals, M&A, research collaborations, and financing transactions.
Best for: Deal trend analysis, partnership scouting, and business development intelligence.
17. Crunchbase / PitchBook
Headquarters: San Francisco, CA / Seattle, WA
While not biotech-specific, Crunchbase and PitchBook are essential for tracking venture funding rounds, private company valuations, and investor activity in the biotech sector. PitchBook’s database provides particularly detailed information on private round terms, cap table structures, and investor participation. For VC investors, these platforms provide the competitive intelligence needed to identify co-investment opportunities and track rival fund activity.
Best for: Venture funding tracking, private company data, investor mapping, and VC competitive intelligence.
Layer 5: Real-World Data & Evidence Platforms
These platforms provide access to clinical and real-world data that investors use to independently assess drug performance, competitive dynamics, and market opportunity — reducing dependence on company-disclosed data.
18. IQVIA
Headquarters: Durham, NC
IQVIA’s data assets are the gold standard for pharmaceutical market intelligence. Their prescription data (covering retail and specialty pharmacy), claims data, and hospital purchasing data provide the most comprehensive view of how drugs are performing commercially. For public equity investors, IQVIA’s weekly prescription data (often accessed via third-party syndication) is the primary tool for tracking drug launch trajectories and competitive market share dynamics.
Best for: Prescription volume tracking, launch curve analysis, market share monitoring, and commercial performance benchmarking.
19. Symphony Health (PurpleLab)
Headquarters: Conshohocken, PA
Symphony Health provides anonymized patient-level claims data that enables investors to track prescription trends, patient switching patterns, and payer coverage dynamics. Their Integrated Dataverse combines pharmacy claims, medical claims, and hospital data into a longitudinal view of patient treatment journeys. For investors analyzing competitive dynamics in therapeutic areas like oncology, immunology, or metabolic disease, Symphony data reveals the patient-level behaviors that aggregate prescription data cannot capture.
Best for: Patient-level claims analysis, switching pattern tracking, and payer coverage intelligence.
20. Tempus AI
Headquarters: Chicago, IL
Tempus’s multimodal data platform — spanning genomic, clinical, and imaging data across 350+ petabytes — is increasingly used by biotech investors for independent pipeline assessment. By analyzing real-world treatment patterns and molecular data, investors can form independent views on which biomarker-defined populations are large enough to support a drug’s commercial thesis. Tempus went public in 2024 at a valuation exceeding $6 billion.
Best for: Genomic and molecular data analysis, biomarker population sizing, and precision medicine market assessment.
Layer 6: News, Research & Expert Intelligence
These platforms provide the qualitative intelligence — expert opinions, analyst perspectives, and breaking news — that gives context to quantitative data and often provides the earliest signals of pipeline and competitive shifts.
21. STAT News (STAT+)
Headquarters: Boston, MA | Domain Authority: 85
STAT is the premier news publication for biotech investors. Their STAT+ subscription provides exclusive reporting, analysis, and early coverage of clinical data, regulatory decisions, and industry dynamics that routinely moves biotech stocks. STAT’s journalists are among the most connected in the industry, often breaking news before companies issue press releases. For professional biotech investors, a STAT+ subscription is essentially mandatory.
Best for: Breaking biotech news, investigative reporting, and early intelligence on clinical and regulatory developments.
22. Endpoints News
Headquarters: Cambridge, MA
Endpoints News has built a dedicated following among biotech executives and investors through fast, focused coverage of clinical trial results, deal activity, and pipeline developments. Their daily Early Edition email is a morning staple for thousands of industry professionals. With over 125,000 subscribers, Endpoints has become an essential information channel alongside STAT.
Best for: Daily biotech news coverage, clinical trial results analysis, and deal reporting.
23. BioMed Nexus
Headquarters: Daily newsletter and digital platform
BioMed Nexus delivers a fast, daily industry briefing covering biotech, medtech, and pharma for over 85,000 professionals. The combination of daily brevity with deeper editorial analysis across all three verticals simultaneously fills a gap that single-sector publications do not cover. For investors tracking cross-sector dynamics — like how medtech diagnostics inform biotech pipeline assessments, or how pharma commercial strategies affect biotech M&A valuations — the tri-sector perspective provides context that specialized publications miss.
Best for: Daily tri-sector briefing (biotech + medtech + pharma), high-signal updates, and cross-vertical industry context.
24. KOL / Expert Network Platforms
Multiple providers including GLG, AlphaSights, Guidepoint, and Third Bridge
Expert networks connect investors with key opinion leaders (KOLs) — the physicians, researchers, and former industry executives who can provide on-the-ground perspectives that public data sources cannot. A 30-minute call with an oncologist who prescribes a drug daily reveals more about competitive positioning than a hundred slides of market research. For biotech investors, expert calls are often the decisive input in investment decisions, particularly around clinical data interpretation and commercial potential assessment.
Best for: Clinical data interpretation, prescriber behavior insights, commercial potential assessment, and due diligence.
25. SEC EDGAR / Insider Transaction Trackers
Headquarters: Washington, DC | Cost: Free
SEC filings — 10-Ks, 10-Qs, proxy statements, 13Fs, and Form 4 insider transactions — contain information that no commercial platform can replicate. Insider buying and selling patterns in biotech often signal upcoming catalysts or management confidence shifts before public announcements. Tools that aggregate and alert on insider transactions (including OpenInsider, SecForm4, and premium services) provide actionable signals that many biotech investors incorporate into their process.
Best for: Insider transaction monitoring, institutional ownership analysis, and primary-source regulatory and financial disclosures.
How Investors Assemble the Stack
No single platform provides a complete solution. Here is how a typical biotech investment workflow maps across these layers:
Idea generation starts with pipeline databases (Evaluate, Cortellis, Citeline) to identify therapeutic areas with favorable competitive dynamics, and news platforms (STAT, Endpoints, BioMed Nexus) to catch emerging catalysts.
Due diligence involves ClinicalTrials.gov for protocol analysis, Biomedtracker for probability of success scoring, DealForma for comparable deal valuation, and expert network calls for clinical context.
Position sizing uses Bloomberg or FactSet for financial modeling, IQVIA for prescription data tracking, and Evaluate for consensus revenue forecasts.
Ongoing monitoring relies on daily news coverage, PDUFA calendar tracking, prescription data updates, and insider transaction alerts.
The investors who outperform are not necessarily those with the most expensive tools. They are the ones who assemble the right combination for their strategy and use each platform for its specific strength rather than trying to force one tool to do everything.
What’s Changing in 2026
AI is entering investment research. Platforms like AlphaSense are using large language models to analyze vast document sets, identify patterns across filings, and surface non-obvious connections. Expect AI-powered research assistants to become standard tools by 2027.
Real-world data is democratizing. IQVIA prescription data was once available only to institutional investors paying six-figure subscriptions. Newer platforms are making similar data available at lower price points, potentially leveling the information playing field.
Regulatory intelligence is becoming real-time. Automated FDA monitoring, ML-powered guidance analysis, and predictive regulatory models are compressing the time between a regulatory signal and an investment decision.
Cross-sector analysis is becoming essential. As biotech, medtech, and pharma converge — through companion diagnostics, digital therapeutics, and platform medicine — investors increasingly need tools that span all three sectors rather than specializing in one.
Methodology
Platforms included in this guide were selected based on adoption among professional biotech investors, data quality and coverage, analytical capabilities, and relevance to investment decision-making in 2026. Free and premium tools are both included. This guide focuses on investment-oriented platforms; clinical operations tools are covered in our separate Digital Health Platforms guide.
Does your platform power biotech investment decisions? We update this guide quarterly and welcome submissions. Contact our editorial team with your company details for consideration in the next update.
Stay Ahead of the Market
In biotech investing, information advantage is everything. The platforms in this guide are the infrastructure that separates informed capital allocation from speculation.
Subscribe to BioMed Nexus for daily coverage of the clinical catalysts, deal activity, and pipeline shifts that move biotech markets.
Last updated: March 2026. Next update: June 2026.
